Stuart Marcus, MD, PhD

Founder And Chief Scientific Officer at SonALAsense

Stuart Marcus, MD, PhD has a diverse work experience spanning over several decades. Stuart is currently the Founder, Chief Medical Officer, and Chief Scientific Officer at SonALAsense, a clinical-stage company focused on developing ALA sonodynamic therapy (SDT) for the treatment of recurrent glioblastoma multiforme (rGBM) and other deadly cancers. In this role, Dr. Marcus utilizes MRI-guided focused ultrasound and aminolevulinic acid to selectively target and kill tumor cells. Prior to this, they served as the Founder, Chief Executive Officer, and Chief Medical Officer at SonALAsense.

Dr. Marcus also owns their own consulting firm, SLM Clinical Development Consulting, LLC, which they started in 2017. Stuart was previously associated with SUN PHARMA as an Associate Vice President, Scientific Affairs from 2016 to 2017. Before that, they held the position of VP Scientific Affairs and CMO at DUSA Pharmaceuticals Inc., a dermatology company known for its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. DUSA Pharmaceuticals Inc. was later acquired by SUN PHARMA.

Earlier in their career, Dr. Marcus worked at Daiichi Sankyo, Inc., where they served as the Director of Hematology/Oncology Development. Stuart was responsible for the creation and supply of innovative pharmaceutical products to address unmet medical needs. Prior to that, they held the position of Group Director, Antineoplastic Drug Development at American Cyanamid (Medical Research Division), a subsidiary of Pfizer.

Overall, Dr. Stuart Marcus has demonstrated expertise in clinical development, scientific affairs, and drug development throughout their career.

Stuart Marcus, MD, PhD, pursued their education in a diligent and focused manner. Stuart began their academic journey at Syracuse University from 1968 to 1972, where they earned their Ph.D. in Molecular Biology. Afterwards, they proceeded to the Albert Einstein College of Medicine, where they pursued further studies from 1978 to 1983. At the college, they obtained both an MD and an earlier Ph.D. in Medicine with a specialization in biochemistry. Stuart Marcus's educational background demonstrates their dedication to acquiring knowledge in the fields of Molecular Biology, Medicine, and Biochemistry.

Links

Previous companies

Daiichi Sankyo logo

Timeline

  • Founder And Chief Scientific Officer

    April 1, 2023 - present

  • Founder, Chief Medical Officer and Chief Scientific Officer

    November, 2021

  • Founder, Chief Executive Officer and Chief Medical Officer

    January, 2019